Administration of granulocyte colony-stimulating factor induces immunomodulation, recruitment of T regulatory cells,...

Area of Science:

• Immunology
• Cardiology
• Parasitology

Background:

• Chagas disease, caused by Trypanosoma cruzi, is a major cause of heart failure in Latin America.
• Previous studies indicated granulocyte colony-stimulating factor (G-CSF) improves heart function in chronic Chagas disease models.

Purpose of the Study:

• To investigate the underlying mechanisms of G-CSF's beneficial effects in chronic Chagas disease.
• To explore G-CSF's impact on cardiac inflammation, fibrosis, immune response, and parasitism.

Main Methods:

• Mice with chronic T. cruzi infection received human recombinant G-CSF treatment.
• Cardiac inflammation, fibrosis, gene expression (syndecan-4, ICAM-1, galectin-3), cytokine profiles (IFN-γ, TNF-α, IL-10, TGF-β), regulatory T cell populations (CD3+Foxp3+), and parasite load were assessed.

Main Results:

• G-CSF treatment significantly reduced cardiac inflammation and fibrosis.
• Key molecular markers of inflammation and fibrosis, including syndecan-4, ICAM-1, and galectin-3, were decreased.
• G-CSF modulated cytokine profiles, decreasing pro-inflammatory IFN-γ and TNF-α while increasing anti-inflammatory IL-10 and TGF-β.
• A notable increase in regulatory T cells (Treg) was observed in the hearts of G-CSF-treated mice.
• Parasitism was reduced following G-CSF administration.

Conclusions:

• G-CSF treatment demonstrates therapeutic potential for Chagas disease by reducing cardiac pathology.
• The beneficial effects of G-CSF involve the induction of regulatory T cells and subsequent immunosuppression.
• G-CSF may offer a novel therapeutic strategy for managing heart complications associated with Chagas disease.